Neurocrine Biosciences

This study tests whether valbenazine can help people with tardive dyskinesia (uncontrollable movements) who still have symptoms while taking or after stopping another drug. About 50 adults with schizophrenia, bipolar disorder, or major depression will take valbenazine for 24 week…

This study tests an experimental drug called NBI-1117568 to see if it can delay the return of schizophrenia symptoms in adults who are already stable on the drug. About 560 participants will first receive the drug openly, then be randomly assigned to continue the drug or switch t…

This study tests whether adding the experimental drug NBI-1065845 to standard antidepressants can delay the return of depression symptoms in adults with major depressive disorder. About 550 participants who have not fully responded to current antidepressants will receive either t…

This study is testing an experimental drug called crinecerfont in 6 infants under 2 years old who have congenital adrenal hyperplasia (CAH), a condition where the body can't make certain hormones properly. The goal is to see how the drug moves through the body and if it is safe. …

This study tests an experimental drug called NBI-1117568 to see if it can improve schizophrenia symptoms better than a placebo. About 284 adults with schizophrenia who need hospital care will take the drug or a dummy pill for 5 weeks. The main goal is to measure changes in sympto…

This study tests a new medication, NBI-1117570, to see if it can improve symptoms like confusion, mood changes, and unusual behavior in adults with schizophrenia who need hospital care. About 120 people aged 18 to 55 will receive either the drug or a placebo for 35 days. The goal…

This study tests an experimental drug, NBI-1065890, against a placebo in 100 adults with tardive dyskinesia (uncontrollable movements) caused by psychiatric medications. Participants must have schizophrenia, bipolar disorder, or similar conditions. The main goal is to see if the …

This study tests whether adding NBI-1065845 to standard antidepressants can better ease depression symptoms in adults who haven't gotten enough relief from their current medication. About 200 people will receive either the study drug or a placebo for 8 weeks, and researchers will…

This study tests whether adding NBI-1065845 to standard antidepressants can better reduce depression symptoms in adults with major depressive disorder who haven't improved enough with current medication. About 200 participants will receive either the study drug or a placebo for 8…

This study tests an experimental drug called NBI-1117568 to see if it can improve schizophrenia symptoms like hallucinations and confusion in adults who need hospital care. About 284 participants will receive either the drug or a placebo for 5 weeks while staying in the hospital.…